PCM
PFE icon

Prelude Capital Management’s Pfizer PFE Stock Holding History

Prelude Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.77M Buy
134,252
+15,110
+13% +$402K 0.29% 86
2025
Q4 		$2.97M Buy
119,142
+96,319
+422% +$2.43M 0.22% 96
2025
Q3 		$582K Buy
22,823
+7,415
+48% +$183K 0.05% 457
2025
Q2 		$373K Sell
15,408
-74,426
-83% -$1.74M 0.04% 533
2025
Q1 		$2.28M Buy
89,834
+20,503
+30% +$537K 0.17% 137
2024
Q4 		$1.84M Buy
69,331
+12,262
+21% +$333K 0.12% 205
2024
Q3 		$1.65M Buy
57,069
+1,447
+3% +$42.2K 0.1% 263
2024
Q2 		$1.56M Buy
55,622
+3
+0% +$83 0.11% 234
2024
Q1 		$1.54M Sell
55,619
-10,212
-16% -$283K 0.08% 295
2023
Q4 		$1.9M Buy
65,831
+55,612
+544% +$1.68M 0.13% 180
2023
Q3 		$339K Buy
10,219
+1,096
+12% +$38.8K 0.02% 609
2023
Q2 		$335K Buy
9,123
+1,837
+25% +$71.5K 0.02% 595
2023
Q1 		$297K Sell
7,286
-8,148
-53% -$352K 0.02% 646
2022
Q4 		$791K Sell
15,434
-21,896
-59% -$1.05M 0.04% 431
2022
Q3 		$1.63M Buy
37,330
+18,755
+101% +$911K 0.06% 284
2022
Q2 		$974K Sell
18,575
-25,093
-57% -$1.28M 0.03% 539
2022
Q1 		$2.26M Sell
43,668
-22,520
-34% -$1.17M 0.07% 298
2021
Q4 		$3.91M Buy
66,188
+40,464
+157% +$2M 0.1% 138
2021
Q3 		$1.11M Buy
25,724
+19,905
+342% +$882K 0.03% 522
2021
Q2 		$228K Sell
5,819
-40,144
-87% -$1.56M 0.01% 1331
2021
Q1 		$1.67M Buy
45,963
+35,303
+331% +$1.25M 0.04% 401
2020
Q4 		$392K Buy
10,660
+2,724
+34% +$99.9K 0.01% 807
2020
Q3 		$276K Buy
+7,936
New +$278K 0.01% 588
2018
Q4 		– Sell
-30,154
Closed -$1.26M – 2076
2018
Q3 		$1.26M Buy
+30,154
New +$1.16M 0.07% 308
2017
Q2 		– Sell
-3,095
Closed -$100K – 1790
2017
Q1 		$100K Sell
3,095
-32,549
-91% -$1.03M 0.01% 783
2016
Q4 		$1.1M Sell
35,644
-26,842
-43% -$819K 0.13% 189
2016
Q3 		$2.01M Buy
62,486
+5,592
+10% +$187K 0.21% 97
2016
Q2 		$1.9M Buy
+56,894
New +$1.82M 0.27% 98
2015
Q4 		– Sell
-17,538
Closed -$523K – 1633
2015
Q3 		$523K Buy
17,538
+3,083
+21% +$98.9K 0.08% 268
2015
Q2 		$460K Sell
14,455
-164
-1% -$5.34K 0.06% 332
2015
Q1 		$483K Sell
14,619
-20,302
-58% -$645K 0.07% 354
2014
Q4 		$1.03M Buy
34,921
+4,855
+16% +$139K 0.15% 148
2014
Q3 		$844K Sell
30,066
-8,461
-22% -$237K 0.12% 212
2014
Q2 		$1.08M Buy
38,527
+12,974
+51% +$370K 0.14% 167
2014
Q1 		$779K Sell
25,553
-481
-2% -$14.3K 0.1% 255
2013
Q4 		$757K Buy
26,034
+12,733
+96% +$371K 0.12% 232
2013
Q3 		$363K Sell
13,301
-25,066
-65% -$682K 0.06% 374
2013
Q2 		$1.02M Buy
+38,367
New +$1.06M 0.22% 106

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Prelude Capital Management's PFE Position: Q1 2026 in Review

Prelude Capital Management increased its Pfizer (PFE) stake by 13% in Q1 2026, buying an estimated $402K and bringing the position to 134,252 shares worth $3.77M. The position accounts for 0.29% of the portfolio, ranked #86.

Prelude Capital Management first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $3.91M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Prelude Capital Management held 134,252 shares of Pfizer worth $3.77M as of Q1 2026.
  • Prelude Capital Management bought 15,110 Pfizer shares in Q1 2026, an estimated $402K.
  • Pfizer made up 0.29% of Prelude Capital Management's portfolio in Q1 2026, its #86 holding.
  • Prelude Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
  • Prelude Capital Management's Pfizer position peaked at $3.91M in Q4 2021.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.